Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study
Purpose: In the MONALEESA-3 Phase III trial of patients with hormone receptor–positive human epidermal growth factor receptor–negative advanced breast cancer, ribociclib plus fulvestrant significantly improved progression-free survival (PFS) and overall survival (OS). Here, we present patient-report...
Main Authors: | Peter A. Fasching, J. Thaddeus Beck, Arlene Chan, Michele De Laurentiis, Francisco J. Esteva, Guy Jerusalem, Patrick Neven, Xavier Pivot, Giulia V. Bianchi, Miguel Martin, David Chandiwana, Brad Lanoue, Antonia Ridolfi, Yingbo Wang, Karen Rodriguez Lorenc, Arnd Nusch |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-12-01
|
Series: | Breast |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0960977620301867 |
Similar Items
-
Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7)
by: Nadia Harbeck, et al.
Published: (2020-07-01) -
Fulvestrant in endocrine therapy of recurrent and metastatic breast cancer
by: L Yu Vladimirova
Published: (2016-12-01) -
Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial
by: Gabriel N. Hortobagyi
Published: (2018-10-01) -
Should All Patients With HR-Positive HER2-Negative Metastatic Breast Cancer Receive CDK 4/6 Inhibitor As First-Line Based Therapy? A Network Meta-Analysis of Data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT Trials
by: Valentina Rossi, et al.
Published: (2019-10-01) -
Fulvestrant in treatment for metastatic breast cancer
by: L. Yu. Vladimirova, et al.
Published: (2019-12-01)